These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 15784320

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Susceptibility to amoxycillin-clavulanate among clinical isolates of Escherichia coli resistant to cefoxitin.
    Fernandez-Cuenca F, Martinez-Martinez L, Amblar G, Biedenbach DJ, Jones RN, Pascual A.
    Clin Microbiol Infect; 2006 Feb; 12(2):197-8. PubMed ID: 16441464
    [No Abstract] [Full Text] [Related]

  • 4. Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta-lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate.
    Lagacé-Wiens PR, Nichol KA, Nicolle LE, DeCorby M, McCracken M, Mulvey MR, Zhanel GG.
    J Antimicrob Chemother; 2006 Jun; 57(6):1262-3. PubMed ID: 16565157
    [No Abstract] [Full Text] [Related]

  • 5. Urine bactericidal activity against resistant Escherichia coli in an in vitro pharmacodynamic model simulating urine concentrations obtained after 2000/125 mg sustained-release co-amoxiclav and 400 mg norfloxacin administration.
    Alou L, Aguilar L, Sevillano D, Giménez MJ, Cafini F, Valero E, Relaño MT, Prieto J.
    J Antimicrob Chemother; 2006 Apr; 57(4):714-9. PubMed ID: 16492718
    [Abstract] [Full Text] [Related]

  • 6. Susceptibility of Escherichia coli to the amoxycillin-clavulanate combination: which recommendations should be used to provide relevant information to clinicians?
    Patry I, Hocquet D, Talon D, Plesiat P, Bertrand X.
    Clin Microbiol Infect; 2005 Mar; 11(3):237-40. PubMed ID: 15715724
    [Abstract] [Full Text] [Related]

  • 7. Amoxicillin/clavulanate (Augmentin) resistant Escherichia coli in bacterial peritonitis after abdominal surgery--clinical outcome in ICU patients.
    Rahnama'i MS, Wagenvoort JH, van der Linden CJ.
    Neth J Med; 2009 May; 67(5):173-6. PubMed ID: 19581666
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In vitro combined effect of co-amoxiclav concentrations achievable in serum after a 2000/125 mg oral dose, and polymorphonuclear neutrophils against strains of Streptococcus pneumoniae exhibiting decreased susceptibility to amoxicillin.
    Amores R, Alou L, Giménez MJ, Sevillano D, Gómez-Lus ML, Aguilar L, Prieto J.
    Int J Antimicrob Agents; 2004 Jul; 24(1):79-82. PubMed ID: 15225866
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Relationships between resistance to cefoxitin, ciprofloxacin and amoxicillin-clavulanic acid in Escherichia coli clinical isolates].
    Fernández-Cuenca F, Amblar G, Pascual A, Martínez-Martínez L.
    Enferm Infecc Microbiol Clin; 2005 Oct; 23(8):510-1. PubMed ID: 16185572
    [No Abstract] [Full Text] [Related]

  • 15. In vitro activity of co-amoxiclav acid against clinical isolates of Escherichia coli.
    Bertrand X, Talon D.
    J Antimicrob Chemother; 2001 May; 47(5):725-6. PubMed ID: 11328800
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Lower urinary tract infections: bacterial epidemiology and recommendations].
    Bergogne-Bérézin E.
    Prog Urol; 2008 Feb; 18(1 Suppl FMC):F11-4. PubMed ID: 18773847
    [Abstract] [Full Text] [Related]

  • 18. Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents.
    Koeth LM, Good CE, Appelbaum PC, Goldstein EJ, Rodloff AC, Claros M, Dubreuil LJ.
    J Antimicrob Chemother; 2004 Jun; 53(6):1039-44. PubMed ID: 15128729
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of amoxycillin-clavulanate in an experimental model of murine pneumonia caused by AmpC-non-hyperproducing clinical isolates of Escherichia coli resistant to cefoxitin.
    Docobo-Pérez F, Fernández-Cuenca F, Pachón-Ibáñez ME, Pascual A, Pichardo C, Martínez-Martínez L, Pachón J.
    Clin Microbiol Infect; 2008 Jun; 14(6):582-7. PubMed ID: 18294246
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of cefminox compared with amoxicillin/clavulanic acid as a single dose for the prevention of intra-abdominal sepsis in mice intraperitoneally infected with different strains of Escherichia coli and one strain of Bacteroides fragilis.
    Huelves L, Gracia M, Del Prado G, Rodríguez-Cerrato V, Martínez-Marín C, Ponte C, Soriano F, Coronel P, Gimeno M, Blanco J.
    Int J Antimicrob Agents; 2006 Aug; 28(2):151-3. PubMed ID: 16815688
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.